Fuat Aksoy

Dr. Fuat Aksoy

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2005 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
IKIrfan Kutlar
Irfan Kutlar
FAFuat Aksoy
Fuat Aksoy
OKOya Koyluoglu
Oya Koyluoglu
MUMete Gurol Ugur
Mete Gurol Ugur
OBOzcan Balat
Ozcan Balat
MTMehmet Tarakcioglu
Mehmet Tarakcioglu

1 June 2025 in Experimental and Clinical Transplantation
Verified
Other
Closed access
FAFuat Aksoy
Fuat Aksoy
HDHalit Ziya Dundar
Halit Ziya Dundar
ADAylin Bican Demir
Aylin Bican Demir
MKMurat Kiyici
Murat Kiyici
EKEkrem Kaya
Ekrem Kaya
We report a case of neurotoxicity as a side effect of a calcineurin inhibitor (tacrolimus), which is used as an immunosuppressive drug after liver transplant. Our patient had chronic hepatic failure due to Budd-Chiari syndrome and underwent a liver transplant after an appropriate deceased donor organ was obtained. After organ transplant surgery, he was kept under the effect of an immunosuppressive drug (tacrolimus) with daily control of the level of drug in his blood to avoid drug toxicity. Despite the level of drug in his blood being within the ideal range, the patient developed neurotoxicity that presented as weakness of his extremities. Appropriate diagnostic tests were done, and all proved that these signs and symptoms were related to the use of tacrolimus. Therefore, the drug was changed to cyclosporine. After a few months, the patient regained normal neurological functions of his extremities. We should take precautions to monitor neurological symptoms and signs while we administer calcineurin inhibitors.

1 December 2024 in Turkish Journal of Surgery
Verified
Journal Article
Open access
PDF file
FAFuat Aksoy
Fuat Aksoy
EGErhan Gökçe
Erhan Gökçe
EBEyüp Anıl Balkan
Eyüp Anıl Balkan
HDHalit Ziya Dündar
Halit Ziya Dündar
EKEkrem Kaya
Ekrem Kaya
Objective: It is known that surgical treatment is advantageous in terms of efficacy and survival in colorectal cancer and neuroendocrine tumor liver metastases. Our aim in this study was to determine the results of surgical treatment of non-colorectal (NCR), non-neuroendocrine tumor (NNET) liver metastases (LM). Material and Methods: A total of 125 patients having NCR and NNET were included in the study. Demographic characteristics of the patients, histological features of the tumor, time from resection of the primary tumor to the first diagnosis of liver metastases, synchronous and metachronous presentations of hepatic metastases with primary malignancy, type of resection, postoperative complications, length of hospital stay, and survival were analyzed retrosepctively. Results: Median follow-up time was 21 (1-132) months. Mean overall survival (OS) and mean proression free survival (PFS) were 29.86 ± 2.4 and 21.23 ± 2.1 months respectively. Most of the cases were LM of breast (n= 33, 26.4%), gastric (n= 25, 20.0%) and gastrointestinal stromal tumors (GIST) (n= 16, 12.8%). Interval from resection of primary tumor to the diagnosis of LM was 20.90 ± 28.9 (0-144) months. OS and DFS rates were found respectively as; 78% and 69% at one year, 45% and 38% at three years, 32% and 21% at five years and 3.2% and 1.6% at 10 years. Breast cancer liver metastases had the longest OS and PFS. Pancreatic cancer and gastric cancer group significantly have shorter OS than the other groups. Conclusion: According to our data, the results are better in breast and GIST liver metastases, and the place of surgical treatment in pancreatic and malignant melanoma liver metastases is controversial.

25 April 2023 in Transplantation Proceedings
Verified
Journal Article
Closed access
FAFuat Aksoy
Fuat Aksoy
EGErcument Gurluler
Ercument Gurluler
FCFatih Celik
Fatih Celik
MSMurat Sen
Murat Sen
EBEyup Anil Balkan
Eyup Anil Balkan
EKEkrem Kaya
Ekrem Kaya

29 May 2025 in Life
Verified
Journal Article
Open access
PDF file
FAFuat Aksoy
Fuat Aksoy
SASecil AK-AKSOY
Secil AK-AKSOY
AKAhmet Karamustafaoglu
Ahmet Karamustafaoglu
CTCagla Tekin
Cagla Tekin
MEMelis Ercelik
Melis Ercelik
EKEkrem Kaya
Ekrem Kaya
Surgery is one of the most effective treatment methods for liver metastases developing from primary colorectal cancer (CRC). Despite the widespread application of surgical approaches, recurrence rates remain substantial. Although chemotherapy is frequently employed, the supporting evidence for its efficacy in this context remains inconclusive. In the present study, we aimed to identify potential predictors of post-metastasectomy recurrence by analyzing clinical, pathological, and molecular features of both primary colorectal tumors and their corresponding hepatic metastases. Specifically, we evaluated the expression of epithelial–mesenchymal transition (EMT) markers, cancer stem cell (CSC) markers, and selected oncogenic mRNAs (RAS, mTOR, and CMYC) in tissue samples from 84 patients. RAS and CMYC are well-known proto-oncogenes involved in cell proliferation and survival, while mTOR functions as a central regulator of cell growth and metabolism. Following liver metastasectomy, intra-hepatic recurrence was observed in 40.5% of the cases. Among the molecular markers analyzed, the EMT transcription factor SNAIL—which plays a critical role in cancer cell invasion and metastasis—and mTOR exhibited significantly elevated expression in metastatic lesions from patients who experienced recurrence. While SNAIL expression did not show a clear association with the time to recurrence, increased mTOR expression in metastatic liver tissue was significantly associated with both shorter recurrence-free survival and diminished overall survival (p < 0.001). Results showed that mTOR expression levels could be a clinically relevant predictive indicator of remnant liver recurrence. In patients with liver metastases, the use of mTOR inhibitors may be considered after hepatic metastasectomy.

8 September 2023 in Uludağ Üniversitesi Tıp Fakültesi Dergisi
Verified
Journal Article
Open access
FAFuat Aksoy
Fuat Aksoy
EKEkrem Kaya
Ekrem Kaya
MKMelike Sema Koçbey
Melike Sema Koçbey
BBBurak Büyükpolat
Burak Büyükpolat
Ksantogranülomatöz Kolesistit (KGK), yaygın fibrozis ile karakterize nadir görülen bir kolesistit formudur. Malignite ile karışabilme ve çevre dokulara yapışıklık nedeniyle laparoskopik kolesistektomi (LK) zor olsa da, altın stardart tedavi şeklini oluşturmaktadır. Mevcut çalışma kapsamında, tek merkez tarafından KGK tanısı ile kolesistektomi yapılan hastaların sonuçlarının değerlendirilmesi amaçlanmıştır. 2008-2022 yılları arasında tek merkez tarafından KGK nedeniyle kolesistektomi yapılan 96 hasta çalışmaya dahil edildi. Hastaların demografik verileri, preoperatif tanı, görüntüleme bulguları, bilier drenaj gereksinimi ve yöntemleri, akut pankreatit bulguları (radyoloji + biyokimyasal yöntemler ile), intraoperatif bulgular, açık ameliyata geçme oranları (konversiyon), ameliyat sonrası gelişen komplikasyonlar ve hastanede kalış süresi retrospektif olarak incelendi. Hastaların 68 (%70,8) erkek, 28 (%29,2) kadın idi. Hastaların ortalama yaşı 60.4 ± 13.3 (22-86) idi. En sık başvuru nedeni karın ağrısıydı (%65,6). Preoperatif dönemde 24 (%25) hastaya perkütan ve/veya endoskopik bilier drenaj yöntemleri uygulandı. Hastaların tamamına laparoskopik teknikle ameliyata başlanmış olup, 59 (%61,4) unda açık kolesistektomiye geçilmiştir. Hastaların ortalama yatış süresi 8,75 ± 7,1 olurken, 1 (%1) hastada postoperatif dönemde gelişen pnömoni ve buna bağlı sepsis sonrası mortalite gözlenmiştir. KGK, radyolojik, klinik ve cerrahi olarak malignite ile karışabilmesi bakımından önemlidir. Şüpheli vakalarda frozen değerlendirme yapılmalıdır. Yüksek konversiyon oranları bilinse de laparoskopik kolesistektomi halen altın standart tedavi yöntemi olarak bilinmektedir.